Unknown

Dataset Information

0

Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study.


ABSTRACT: BACKGROUND:Sorafenib, a multi-kinase inhibitor, is approved for the treatment of patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). This study evaluated the efficacy and safety of sorafenib in real-world clinical practice and compared the results to those of the DECISION trial. The clinical features associated with better clinical outcomes after sorafenib treatment were also evaluated. METHODS:This multicenter, retrospective cohort study evaluated 98 patients with progressive RAI-refractory DTC who were treated with sorafenib in six tertiary hospitals in Korea. The primary objective was the progression-free survival (PFS) according to Response Evaluation Criteria In Solid Tumors v1.1. Overall survival, response rate (defined as the best objective response according to Response Evaluation Criteria In Solid Tumors v1.1), and safety were also evaluated. RESULTS:The median PFS was 9.7 months; median overall survival was not reached during follow-up. Partial responses and stable disease were achieved in 25 (25%) and 64 (65%) patients, respectively. Stable disease of >6 months was achieved in 41 (42%) patients. Subgroup analyses identified several prognostic indicators of a better PFS: absence of disease-related symptoms (hazard ratio [HR]?=?0.5; p?=?0.041), lung-only metastasis (HR?=?0.4; p?=?0.048), a daily maintenance dose ?600?mg (HR?=?0.3; p?=?0.005), and a thyroglobulin reduction ?60% (HR?=?0.4; p?=?0.012). The mean daily dose of sorafenib was 666?±?114?mg, and drug withdrawals due to adverse events (AEs) occurred in 13% of patients. AEs and serious AEs were reported in 93 (95%) and 40 (41%) patients, respectively. The most frequent AE was hand-foot skin reaction (76%). CONCLUSIONS:The PFS of progressive RAI-refractory DTC patients treated with sorafenib was consistent with the findings of the DECISION trial. Disease-related symptoms, lung-only metastasis, a daily maintenance dose, and thyroglobulin reduction were significantly associated with PFS. These results suggest that sorafenib is an effective treatment option for patients with progressive RAI-refractory DTC.

SUBMITTER: Kim M 

PROVIDER: S-EPMC6225595 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study.

Kim Mijin M   Kim Tae Hyuk TH   Shin Dong Yeob DY   Lim Dong Jun DJ   Kim Eui Young EY   Kim Won Bae WB   Chung Jae Hoon JH   Shong Young Kee YK   Kim Bo Hyun BH   Kim Won Gu WG  

Thyroid : official journal of the American Thyroid Association 20180216 3


<h4>Background</h4>Sorafenib, a multi-kinase inhibitor, is approved for the treatment of patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). This study evaluated the efficacy and safety of sorafenib in real-world clinical practice and compared the results to those of the DECISION trial. The clinical features associated with better clinical outcomes after sorafenib treatment were also evaluated.<h4>Methods</h4>This multicenter, retrospective cohort study evaluat  ...[more]

Similar Datasets

| S-EPMC4709201 | biostudies-literature
| S-EPMC5531232 | biostudies-other
| S-EPMC7160413 | biostudies-literature
| S-EPMC3107731 | biostudies-literature
| S-EPMC9950494 | biostudies-literature
| S-EPMC5646742 | biostudies-literature
| S-EPMC4570090 | biostudies-literature
2022-11-05 | PXD037968 |
| S-EPMC10570678 | biostudies-literature
| S-EPMC4803478 | biostudies-literature